These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

523 related articles for article (PubMed ID: 28187946)

  • 1. Inducible Caspase-9 Selectively Modulates the Toxicities of CD19-Specific Chimeric Antigen Receptor-Modified T Cells.
    Diaconu I; Ballard B; Zhang M; Chen Y; West J; Dotti G; Savoldo B
    Mol Ther; 2017 Mar; 25(3):580-592. PubMed ID: 28187946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease.
    Brudno JN; Somerville RP; Shi V; Rose JJ; Halverson DC; Fowler DH; Gea-Banacloche JC; Pavletic SZ; Hickstein DD; Lu TL; Feldman SA; Iwamoto AT; Kurlander R; Maric I; Goy A; Hansen BG; Wilder JS; Blacklock-Schuver B; Hakim FT; Rosenberg SA; Gress RE; Kochenderfer JN
    J Clin Oncol; 2016 Apr; 34(10):1112-21. PubMed ID: 26811520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. At the Bench: Chimeric antigen receptor (CAR) T cell therapy for the treatment of B cell malignancies.
    Daniyan AF; Brentjens RJ
    J Leukoc Biol; 2016 Dec; 100(6):1255-1264. PubMed ID: 27789538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fully Human Anti-CD19 CAR T Cells Derived from Systemic Lupus Erythematosus Patients Exhibit Cytotoxicity with Reduced Inflammatory Cytokine Production.
    Dingfelder J; Aigner M; Taubmann J; Minopoulou I; Park S; Kaplan CD; Cheng JK; Van Blarcom T; Schett G; Mackensen A; Lutzny-Geier G
    Transplant Cell Ther; 2024 Jun; 30(6):582.e1-582.e10. PubMed ID: 38548226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimeric antigen receptor T-cell therapies for multiple myeloma.
    Mikkilineni L; Kochenderfer JN
    Blood; 2017 Dec; 130(24):2594-2602. PubMed ID: 28928126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A chimeric antigen receptor-based cellular safeguard mechanism for selective
    Svec M; Dötsch S; Warmuth L; Trebo M; Fräßle S; Riddell SR; Jäger U; D'Ippolito E; Busch DH
    Front Immunol; 2023; 14():1268698. PubMed ID: 38274808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The underlying mechanism of chimeric antigen receptor (CAR)-T cell therapy triggering secondary T-cell cancers: Mystery of the Sphinx?
    Zhou Z; Zhang G; Xu Y; Yang S; Wang J; Li Z; Peng F; Lu Q
    Cancer Lett; 2024 Aug; 597():217083. PubMed ID: 38925363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity.
    Liu E; Tong Y; Dotti G; Shaim H; Savoldo B; Mukherjee M; Orange J; Wan X; Lu X; Reynolds A; Gagea M; Banerjee P; Cai R; Bdaiwi MH; Basar R; Muftuoglu M; Li L; Marin D; Wierda W; Keating M; Champlin R; Shpall E; Rezvani K
    Leukemia; 2018 Feb; 32(2):520-531. PubMed ID: 28725044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy.
    Sheih A; Voillet V; Hanafi LA; DeBerg HA; Yajima M; Hawkins R; Gersuk V; Riddell SR; Maloney DG; Wohlfahrt ME; Pande D; Enstrom MR; Kiem HP; Adair JE; Gottardo R; Linsley PS; Turtle CJ
    Nat Commun; 2020 Jan; 11(1):219. PubMed ID: 31924795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells.
    Kochenderfer JN; Yu Z; Frasheri D; Restifo NP; Rosenberg SA
    Blood; 2010 Nov; 116(19):3875-86. PubMed ID: 20631379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Depletion of T cells
    Klopp A; Schreiber S; Kosinska AD; Pulé M; Protzer U; Wisskirchen K
    Front Immunol; 2021; 12():734246. PubMed ID: 34691041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Durable preservation of antiviral antibodies after CD19-directed chimeric antigen receptor T-cell immunotherapy.
    Hill JA; Krantz EM; Hay KA; Dasgupta S; Stevens-Ayers T; Bender Ignacio RA; Bar M; Maalouf J; Cherian S; Chen X; Pepper G; Riddell SR; Maloney DG; Boeckh MJ; Turtle CJ
    Blood Adv; 2019 Nov; 3(22):3590-3601. PubMed ID: 31743392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Cannabidiol on the Functions of Chimeric Antigen Receptor T Cells in Hematologic Malignancies.
    Chantarat N; Pe KCS; Suppipat K; Vimolmangkang S; Tawinwung S
    Cannabis Cannabinoid Res; 2024 Jun; 9(3):819-829. PubMed ID: 37878339
    [No Abstract]   [Full Text] [Related]  

  • 14. Human CD19-Targeted Mouse T Cells Induce B Cell Aplasia and Toxicity in Human CD19 Transgenic Mice.
    Pennell CA; Barnum JL; McDonald-Hyman CS; Panoskaltsis-Mortari A; Riddle MJ; Xiong Z; Loschi M; Thangavelu G; Campbell HM; Storlie MD; Refaeli Y; Furlan SN; Jensen MC; Kean LS; Miller JS; Tolar J; Osborn MJ; Blazar BR
    Mol Ther; 2018 Jun; 26(6):1423-1434. PubMed ID: 29735365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melatonin as an immunomodulator in CD19-targeting CAR-T cell therapy: managing cytokine release syndrome.
    Zheng N; Long Y; Bai Z; Li J; Wang H; Song DD; Liu HL; Shi JH; Zhao S
    J Transl Med; 2024 Jan; 22(1):58. PubMed ID: 38221609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD19 CAR T cells for multiple sclerosis: Forging further into the new frontier.
    Rankin AW; Shah NN
    Med; 2024 Jun; 5(6):482-484. PubMed ID: 38878763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maintenance therapy for early loss of B-cell aplasia after anti-CD19 CAR T-cell therapy.
    Gabelli M; Oporto-Espuelas M; Burridge S; Chu J; Farish S; Hedges E; Ware K; Williams L; Young L; Alajangi R; Ancliff P; Bartram J; Bonney D; Chenchara L; Chiesa R; Cugno C; Hodby K; Jalowiec KA; Lazareva A; Lucchini G; Mirci-Danicar OC; Mullanfiroze K; Pavasovic V; Rao A; Rao K; Riley L; Samarasinghe S; Shenton G; Silva J; Vora A; Hough R; Amrolia PJ; Ghorashian S
    Blood Adv; 2024 Apr; 8(8):1959-1963. PubMed ID: 37820111
    [No Abstract]   [Full Text] [Related]  

  • 18.
    Pfeiffer A; Thalheimer FB; Hartmann S; Frank AM; Bender RR; Danisch S; Costa C; Wels WS; Modlich U; Stripecke R; Verhoeyen E; Buchholz CJ
    EMBO Mol Med; 2018 Nov; 10(11):. PubMed ID: 30224381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T Cell Activators Exhibit Distinct Downstream Effects on Chimeric Antigen Receptor T Cell Phenotype and Function.
    Underwood S; Jin J; Shao L; Prochazkova M; Shi R; Song HW; Jin P; Shah NN; Somerville RP; Stroncek DF; Highfill SL
    Immunohorizons; 2024 Jun; 8(6):404-414. PubMed ID: 38864817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T-cell malignancies with anti-CD19 chimeric antigen receptor T-cell therapy.
    Martin LJ; Whitmore JB; Shen RR; Neumann F
    Blood Adv; 2024 Aug; 8(15):4144-4148. PubMed ID: 38861341
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 27.